CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gynecology Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gynecology Disease Site Committee, the Gynecology Disease Site Executive Committee, and the CCTG Patient Representative Committee.
The deadline is approaching to submit applications for the 2024-2025 CCTG Practicum.
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Genitourinary Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Genitourinary Disease Site Committee, the Genitourinary Disease Site Executive Committee, and the CCTG Patient Representative Committee.
The CCTG MY13 trial is a phase III non-inferiority randomized controlled trial of fixed duration versus continuous daratumumab among transplant in eligible older adults with newly diagnosed multiple myeloma.
There is little scientific evidence around the effective timing of injectable treatments for multiple myeloma. These patients receive treatment with three medicines - two tablets and an injection - all continued indefinitely until they stop working, or the side effects become unmanageable.
The Frances A Shepherd Award is for investigators or post-graduate trainees, traveling to present CCTG related work at major international meetings. Each award will be approximately $1000 and offered two to three times a year. Applicants who have had their research accepted for oral or poster presentation at an international scientific meeting and have not received another award to support their travel are eligible to apply. The application deadline will be set in the spring and fall to coincide with the major international cancer conferences.
